Jiangsu Pacific Meinuoke Biopharmaceuticals
Taizhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A biopharma company developing innovative biologic therapies for oncology and immunology.
OncologyImmunology
Technology Platform
A proprietary platform for antibody humanization, bispecific antibody engineering, and high-yield biologics manufacturing.
Opportunities
Significant opportunity in the large and growing Chinese oncology drug market, with potential for out-licensing candidates to global partners.
Risk Factors
Clinical development risks and potential pricing pressure from China's national drug procurement policies pose significant threats to commercial viability.
Competitive Landscape
Faces intense competition from global oncology leaders like Roche and Merck, as well as a crowded field of domestic Chinese biotechs developing similar checkpoint inhibitors and antibody therapies.